Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNS10-NPC-GDNF in ALS
NCT02943850Phase 1Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Apr 2017
- Primary completion
- Oct 2019
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, single-blind, single-arm trial of CNS10-NPC-GDNF in amyotrophic lateral sclerosis (ALS), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Safety evaluated by Adverse Events and Serious Adverse Events, post-operative MRI, and clinical laboratory assessments at 12 months. Started Apr 2017; status: completed.
02
Drugs
CNS10-NPC-GDNF
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02943850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02943850.